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Objectives: To compare the performance of European Committee on Antimicrobial Susceptibility Testing
(EUCAST) and CLSI breakpoints following their revision in 2010, for the detection of extended-spectrum b-
lactamase (ESBL) production in Enterobacteriaceae.
Methods: 236 well-characterized clinical isolates (including 118 ESBL producers) were investigated by antibiotic
disc testing with cefpodoxime, ceftriaxone, cefepime, cefotaxime EUCAST (5 mg/disc), ceftazidime EUCAST
(10 mg/disc), cefotaxime CLSI (30 mg/disc) and ceftazidime CLSI (30 mg/disc) with the Kirby–Bauer method.
Additionally, synergy phenomena were recorded between amoxicillin/clavulanic acid discs (20/10 mg/disc)
and cefepime (30 mg/disc), EUCAST cefotaxime (5 mg/disc), EUCAST ceftazidime (10 mg/disc), CLSI cefotaxime
(30 mg/disc) and CLSI ceftazidime [30 mg/disc; disc approximation method (DAM)].
Results: Overall sensitivity of the cefotaxime EUCAST non-susceptible breakpoint equalled sensitivity of the
cefotaxime CLSI ESBL screening breakpoint (99.2%). With the ceftazidime EUCAST non-susceptible breakpoint,
27/118 ESBL-producing isolates were not detected, whereas the ceftazidime CLSI ESBL screening breakpoint
missed 41/118 ESBL-producing isolates. For cefpodoxime the resistant EUCAST breakpoint showed higher sen-
sitivity for ESBL detection compared with the CLSI ESBL screening breakpoint/disc content (100% versus 98.3%,
respectively). Sensitivities of ceftazidime and cefotaxime DAM with CLSI or EUCAST disc contents were compar-
able (sensitivities ranging from 84.7% to 89.8%). DAM with cefepime displayed the highest overall sensitivity
(96.6%). In AmpC-producing isolates, synergy of amoxicillin/clavulanic acid with cefepime showed sensitivity
and specificity for ESBL detection of 100% and 97.4%, respectively.
Conclusions: EUCAST non-susceptible breakpoints for ceftazidime and cefpodoxime detect more ESBL-
producing Enterobacteriaceae isolates compared with corresponding CLSI ESBL screening breakpoints.
Implementation of the cefepime DAM can facilitate ESBL screening, especially in strains producing an AmpC
b-lactamase since the test shows high sensitivity and specificity.
Keywords: breakpoints, cut-offs, Gram-negative
Introduction
The prevalence of extended-spectrum b-lactamase (ESBL) pro-
duction in strains of the Enterobacteriaceae family, such as
Escherichia coli, Klebsiella spp. and Enterobacter spp., has been
increasing continuously during the past decade in Europe and
worldwide.1 – 4 The production on ESBLs can lead to life-
threatening infections with increased morbidity, mortality and
healthcare-associated costs.5 – 8
The Clinical and Laboratory Standards Institute (CLSI) and
the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) recently changed their recommendations concerning
the interpretation and reporting of in vitro drug susceptibility
testing (DST) results. These changes apply to penicillins,
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cephalosporins and monobactams, and are based on limited
clinical data, pharmacokinetics/pharmacodynamics (PK/PD)
properties and MIC distributions.
If the production of an ESBL was confirmed, both institutions
until 2009 recommended to edit all in vitro susceptible and inter-
mediate DST results for penicillins, cephalosporins and monobac-
tams to ‘resistant’ (CLSI),9 or to change interpretative categories
‘susceptible’ and ‘intermediate’ to ‘intermediate’ and ‘resistant’,
respectively (EUCAST).10 In 2010 EUCAST published inhibition-
zone diameter susceptibility breakpoints for cephalosporins in
Enterobacteriaceae that were significantly higher than CLSI
breakpoints up to 2009.11 In parallel, CLSI increased zone diam-
eter susceptibility breakpoints as well.12 Currently, editing of in
vitro susceptibility test results for b-lactams in ESBL-producing
isolates is no longer recommended.13,14 However, for epidemio-
logical and infection control purposes, screening for ESBL pro-
duction in Enterobacteriaceae is still useful (CLSI)13 or even
mandatory (EUCAST).14
In isolates producing an AmpC-type b-lactamase, phenotypic
detection of ESBL production is often hampered by the interfer-
ence of AmpC with ESBL screening and confirmatory tests
leading to false reports to clinicians and, thus, to inadequate
therapy.15,16 In addition, unnecessary time, effort and cost are
generated in the laboratories to further study false-positive
ESBL screening tests resulting from the low specificity of ESBL
screening methods in AmpC-positive isolates.16 As a tool to
counter this problem, cloxacillin-containing Muller–Hinton agar,
which inhibits AmpC activity, has been successfully evaluated.17
Furthermore, cefepime may be the most suitable cephalosporin
for ESBL detection in AmpC-positive isolates since it is less
affected by AmpC than other third-generation cephalosporins,
such as ceftazidime, cefotaxime, cefpodoxime and ceftriaxone.15
The rapid advance of molecular methods for the detection of
ESBL has raised the question of using these techniques as routine
screening methods.18 – 20 However, implementation in routine
clinical diagnostic laboratories is complex and needs personal
resources with specialist qualifications. Moreover, the costs of
molecular screening methods for multidrug-resistant isolates
are still significantly higher than those for phenotypic methods.21
In this study the performance of CLSI screening breakpoints
for ESBL detection in clinical isolates were compared with
EUCAST breakpoints for a set of phenotypically and genotypically
well-characterized Enterobacteriaceae isolates. Many clinical lab-
oratories in Europe are currently adopting the EUCAST system,
although a direct comparison of the performance of CLSI and
EUCAST standards has not yet been reported. EUCAST does not
provide specific screening breakpoints for ESBL; therefore,
EUCAST inhibition zone diameter clinical breakpoints for third-
generation cephalosporins were applied as determinants for
ESBL production.
Methods
Clinical isolates
The 236 Enterobacteriaceae clinical isolates used in this study have
previously been systematically characterized for the production of ESBL
and/or AmpC-type b-lactamases, using phenotypic and molecular
methods (for ESBL, S. Polsfuss, G. V. Bloemberg, J. Giger, V. Meyer, E. C.
Bottger and M. Hombach, unpublished results).22 All isolates had initially
been screened for potential ESBL production on the basis of: (i) positive
CLSI screening breakpoint values for ESBL for at least one third-
generation cephalosporin (cefpodoxime and/or ceftazidime and/or cef-
triaxone and/or cefotaxime); and (ii) observation of a synergy zone
between amoxicillin/clavulanic acid and cefpodoxime and/or ceftazidime
and/or ceftriaxone and/or cefotaxime. For 118/236 isolates ESBL pro-
duction was confirmed by molecular methods, while another 118/236
isolates were ESBL-negative (see Table 1).
Susceptibility testing
For susceptibility testing the disc diffusion method according to Kirby–
Bauer was used. Antibiotic discs (Becton Dickinson, Franklin Lakes, NJ,
USA) were selected, and results were interpreted according to the 2011
guidelines of EUCAST and CLSI.13,14 Screening breakpoint values are
shown in Tables 2–4.
Susceptibility testing was performed on Mueller–Hinton agar
(bioMe´rieux, Marcy L’Etoile, France) using McFarland 0.5 with overnight
cultures and incubated at 358C for 16–18 h.
Table 1. Enterobacteriaceae clinical isolates included in the study
All isolates
(%)
ESBL
producers
AmpC
producers
ESBL and
AmpC
producers
Non-ESBL,
non-AmpC
CTX-M types
SHV ESBL
type
TEM ESBL
type
Group
I
Group
III
Group
IV
All species 236 (100.0) 105 78 13 40
Escherichia coli 131 (55.6) 86 30 2 13 62 1 16 8 1
Klebsiella pneumoniae 31 (13.1) 16 2 1 12 14 2 1
Klebsiella oxytoca 17 (7.2) 2 0 0 15 2a 1a
Enterobacter cloacae 33 (14.0) 0 24 9 0 6 3
Citrobacter sp. 1 (0.4) 0 0 1 0 1
Proteus mirabilis 2 (0.8) 1 1 0 0 1
Othersb 21 (8.9) 0 21 0 0
aOne isolate co-produced both SHV and CTX-M IV.
bOthers comprised Enterobacter aerogenes (8 isolates), Citrobacter freundii (7 isolates), Morganella morganii (2 isolates), Serratia marcescens
(2 isolates) and Salmonella enterica (2 isolates).
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Table 2. Performance parameters of critical diameters and DAM for the detection of ESBL production in 236 Enterobacteriaceae clinical isolates
Method Breakpoint (mm) Interpretation/category Isolates (N)
True False
Sensitivity (%) Specificity (%)positive (N) negative (N) positive (N) negative (N)
Critical diameters
CTX CLSI (30 mg/disc) ≤27 Screening breakpoint CLSI 236 117 48 70 1 99.2 40.7
CTX EUCAST (5 mg/disc) ,18 EUCAST¼R 236 112 63 55 6 94.9 53.4
,21 EUCAST¼I+R 236 117 53 65 1 99.2 44.9
CAZ CLSI (30 mg/disc ) ≤22 Screening breakpoint CLSI 236 77 66 52 41 65.3 55.9
CAZ EUCAST (10 mg/disc) ,19 EUCAST¼R 236 77 67 51 41 65.3 56.8
,22 EUCAST¼I+R 236 91 52 66 27 77.1 44.1
CRO (30 mg/disc) ≤25 Screening breakpoint CLSI 236 117 49 69 1 99.2 41.5
,20 EUCAST¼R 236 100 68 50 18 84.7 57.6
,23 EUCAST¼I+R 236 113 57 61 5 95.8 48.3
CPD (10 mg/disc) ≤17 Screening breakpoint CLSI 236 116 53 65 2 98.3 44.9
,21 EUCAST¼R (no I category) 236 118 44 74 0 100.0 37.3
FEP (30 mg/disc) ,21 EUCAST¼R 236 77 109 9 41 65.3 92.4
,24 EUCAST¼I+R 236 91 93 25 27 77.1 78.8
≤14 CLSI¼R 236 14 117 1 104 11.9 99.2
≤17 CLSI¼I 236 48 114 4 70 40.7 96.6
DAM
CTX CLSI+AMC 236 106 106 12 12 89.8 89.8
CTX EUCAST+AMC 236 103 110 8 15 87.3 93.2
CAZ CLSI+AMC 236 100 116 2 18 84.7 98.3
CAZ EUCAST+AMC 236 102 116 2 16 86.4 98.3
FEP AMC 236 114 106 12 4 96.6 89.8
AMC, amoxicillin/clavulanic acid; CAZ, ceftazidime; CPD, cefpodoxime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; DAM, disc approximation method; I, intermediate category; R,
resistant category.
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Table 3. Performance parameters of critical diameters and DAM for the detection of ESBL production in 91 AmpC-producing Enterobacteriaceae isolatesa
Method Breakpoint (mm) Interpretation/category Isolates (N)
True False
Sensitivity (%) Specificity (%)positive (N) negative (N) positive (N) negative (N)
Critical diameters
CTX CLSI (30 mg/disc) ≤27 Screening breakpoint CLSI 91 13 27 51 0 100.0 34.6
CTX EUCAST (5 mg/disc) ,18 EUCAST¼R 91 13 30 48 0 100.0 38.5
,21 EUCAST¼I+R 91 13 27 51 0 100.0 34.6
CAZ CLSI (30 mg/disc ) ≤22 Screening breakpoint CLSI 91 11 31 47 2 84.6 39.7
CAZ EUCAST (10 mg/disc) ,19 EUCAST¼R 91 11 31 47 2 84.6 39.7
,22 EUCAST¼I+R 91 13 27 51 0 100.0 34.6
CRO (30 mg/disc) ≤25 Screening breakpoint CLSI 91 13 32 46 0 100.0 41.0
,20 EUCAST¼R 91 13 36 42 0 100.0 46.2
,23 EUCAST¼I+R 91 13 33 45 0 100.0 42.3
CPD (10 mg/disc) ≤17 Screening breakpoint CLSI 91 13 25 53 0 100.0 32.1
,21 EUCAST¼R (no I category) 91 13 21 57 0 100.0 26.9
FEP (30 mg/disc) ,21 EUCAST¼R 91 10 75 3 3 76.9 96.2
,24 EUCAST¼I+R 91 12 64 14 1 92.3 82.1
≤14 CLSI¼R 91 1 78 0 12 7.7 100.0
≤17 CLSI¼I 91 5 78 0 8 38.5 100.0
DAM
CTX CLSI+AMC 91 10 77 1 3 76.9 98.7
CTX EUCAST+AMC 91 9 78 0 4 69.2 100.0
CAZ CLSI+AMC 91 7 78 0 6 53.8 100.0
CAZ EUCAST+AMC 91 7 78 0 6 53.8 100.0
FEP AMC 91 13 76 2 0 100.0 97.4
AMC, amoxicillin/clavulanic acid; CAZ, ceftazidime; CPD, cefpodoxime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; DAM, disc approximation method; I, intermediate category; R,
resistant category.
aDetailed numbers are listed in Table 1.
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Table 4. Performance parameters of critical diameters and DAM for the detection of ESBL production in 145 Enterobacteriaceae isolates without AmpC productiona
Method Breakpoint (mm) Interpretation/category Isolates (N)
True False
Sensitivity (%) Specificity (%)positive (N) negative (N) positive (N) negative (N)
Critical diameters
CTX CLSI (30 mg/disc) ≤27 Screening breakpoint CLSI 145 104 21 19 1 99.0 52.5
CTX EUCAST (5 mg/disc) ,18 EUCAST¼R 145 99 33 7 6 94.3 82.5
,21 EUCAST¼I+R 145 104 26 14 1 99.0 65.0
CAZ CLSI (30 mg/disc ) ≤22 Screening breakpoint CLSI 145 66 35 5 39 62.9 87.5
CAZ EUCAST (10 mg/disc) ,19 EUCAST¼R 145 66 36 4 39 62.9 90.0
,22 EUCAST¼I+R 145 78 25 15 27 74.3 62.5
CRO (30 mg/disc) ≤25 Screening breakpoint CLSI 145 104 17 23 1 99.0 42.5
,20 EUCAST¼R 145 87 32 8 18 82.9 80.0
,23 EUCAST¼I+R 145 100 24 16 5 95.2 60.0
CPD (10 mg/disc) ≤17 Screening breakpoint CLSI 145 103 28 12 2 98.1 70.0
,21 EUCAST¼R (no I category) 145 105 23 17 0 100.0 57.5
FEP (30 mg/disc) ,21 EUCAST¼R 145 67 34 6 38 63.8 85.0
,24 EUCAST¼I+R 145 79 29 11 26 75.2 72.5
≤14 CLSI¼R 145 13 39 1 92 12.4 97.5
≤17 CLSI¼I 145 43 36 4 62 41.0 90.0
DAM
CTX CLSI+AMC 145 96 29 11 9 91.4 72.5
CTX EUCAST+AMC 145 94 32 8 11 89.5 80.0
CAZ CLSI+AMC 145 93 38 2 12 88.6 95.0
CAZ EUCAST+AMC 145 95 38 2 10 90.5 95.0
FEP AMC 145 101 30 10 4 96.2 75.0
AMC, amoxicillin/clavulanic acid; CAZ, ceftazidime; CPD, cefpodoxime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; DAM, disc approximation method; I, intermediate category; R,
resistant category.
aDetailed numbers are listed in Table 1.
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Comparison of EUCAST and CLSI ESBL screening
breakpoints
CLSI-recommended inhibition zone diameter breakpoints for third-
generation cephalosporins for ESBL screening were compared with
EUCAST clinical breakpoints for their ability to detect ESBL-producing clini-
cal isolates.13,14 EUCAST eliminates the intermediate category for some
antibiotics, such as cefpodoxime. The resulting single breakpoint was
used as the ESBL-screening breakpoint. However, for other third-
generation cephalosporins, like ceftazidime and cefotaxime, an inter-
mediate (or indeterminate) zone is retained, but not specifically men-
tioned in the EUCAST breakpoint tables. In such cases EUCAST provides
different breakpoints for clinical resistance and susceptibility. For
example, with ceftazidime all isolates showing an inhibition zone
≥22 mm are considered clinically susceptible, and all isolates presenting
an inhibition zone ,19 mm are considered clinically resistant. Isolates
showing an inhibition zone of 19–21 mm are not specifically categorized
in the EUCAST guidelines, and the intermediate zone is only implied. A
non-susceptible breakpoint was deduced from the EUCAST susceptible
breakpoint, e.g. if EUCAST defines a ceftazidime inhibition zone
≥22 mm as susceptible, a breakpoint of ,22 mm was referred to in
this publication as the corresponding non-susceptible breakpoint. Non-
susceptible isolates in this definition include, therefore, all intermediate
and resistant isolates (see Tables 2–4).
Disc approximation method (DAM)
DAM with amoxicillin/clavulanic acid was conducted as described.23
Synergy phenomena were recorded between amoxicillin/clavulanic acid
discs (20/10 mg/disc) and/or cefepime (30 mg/disc), and/or EUCAST cefo-
taxime (5 mg/disc), and/or EUCAST ceftazidime (10 mg/disc), and/or CLSI
cefotaxime (30 mg/disc) and/or CLSI ceftazidime (30 mg/disc) discs. Anti-
biotic discs were placed 30 mm apart (centre to centre). b-Lactam
inhibitor-mediated enhancement of a third-generation cephalosporin
inhibition zone was interpreted as synergy positive. Molecular methods
were considered the gold standard for the calculation of performance
parameters.
Results
Comparison of CLSI and EUCAST inhibition zone
breakpoints for third-generation cephalosporins
For cefotaxime, overall sensitivity of EUCAST non-susceptible
breakpoints for ESBL with corresponding EUCAST loaded discs
equalled those of CLSI ESBL screening breakpoints/loads (sensi-
tivity 99.2%, see also Table 2). If the EUCAST resistant breakpoint
was applied, sensitivity decreased from 99.2% (1/118 ESBL-
producing isolates not detected) to 94.9% (6/118 ). For ceftazi-
dime, sensitivity of the EUCAST non-susceptible breakpoint for
ESBL with corresponding EUCAST disc content was higher than
that for the CLSI ESBL screening breakpoint/load (77.1% and
65.3% for EUCAST and CLSI, respectively). If the EUCAST resistant
breakpoint was applied, sensitivity equalled that of the CLSI
breakpoint/disc content. When the EUCAST non-susceptible
breakpoint for ceftriaxone was used, sensitivity for ESBL detec-
tion compared with the CLSI ESBL screening breakpoint/disc
content was lower (95.8% versus 99.2%, respectively). For cefpo-
doxime the non-susceptible EUCAST breakpoint showed higher
sensitivity for ESBL detection compared with the CLSI ESBL
screening breakpoint/load (100% versus 98.3%, respectively).
In AmpC-producing isolates (n¼91), of which 13 were ESBL
positive (see Table 1), all diameter breakpoints showed low
specificities for ESBL detection, except the EUCAST breakpoints
for cefepime, which displayed a specificity of 82.1% and 96.2%
for the non-susceptible and resistant breakpoints, respectively
(Table 3).
In non-AmpC-producing isolates (n¼145) the EUCAST non-
susceptible breakpoint for cefpodoxime was the most sensitive
single marker for ESBL production (sensitivity 100%, see
Table 4). In comparison, the corresponding CLSI breakpoint
showed a sensitivity of 98.1% (2 out of 105 ESBL-producing iso-
lates not detected). Sensitivities of EUCAST and CLSI breakpoints
for cefotaxime were equal (99.0%, 1 out of 105 ESBL positive iso-
lates not detected). For third-generation cephalosporins, only the
EUCAST non-susceptible breakpoint for ceftriaxone showed lower
sensitivity in non-AmpC-producing isolates than the CLSI ESBL
screening breakpoint (sensitivities of 95.2% versus 99.0%,
respectively).
Comparison of DAM with CLSI and EUCAST disc contents
Sensitivities of DAM with amoxicillin/clavulanic acid (clavulanic
acid serving as the ESBL inhibitor) and ceftazidime or cefotaxime
discs with CLSI or EUCAST disc contents, respectively, were
similar (ranging from 84.7% to 89.8%, see Table 2). Considering
all isolates independent of the production of an AmpC-type
b-lactamase, DAM with amoxicillin/clavulanic acid and cefepime
displayed the highest sensitivity (96.6%). The other combinations
had sensitivities less than 90%.
In AmpC-producing isolates, synergy of amoxicillin/
clavulanic-acid with cefepime showed a sensitivity and specificity
of 100% and 97.9%, respectively. The other DAMs in AmpC-
producing isolates showed low sensitivity (Table 3).
Discussion
In 2010 EUCAST and CLSI changed their guidelines concerning
ESBL detection and interpretation.11,12 Reporting of penicillins
and cephalosporins as resistant, independent of in vitro results,
is no longer recommended. However, detection of ESBL is still
considered useful (CLSI, 2011)13 or even mandatory (EUCAST,
2011)14 for epidemiological purposes. Additionally, it remains
controversial as to whether the presence of ESBL-producing bac-
terial strains alone is an independent risk factor that may influ-
ence the selection of an adequate therapy.24 – 28 CLSI inhibition
zone screening breakpoints for ESBL have been evaluated in
several studies, as it has for DAM.26,29 The current adoption of
the new EUCAST guidelines in Europe raises the question of
how sensitive and specific EUCAST clinical breakpoints are for
third-generation cephalosporins, in comparison with CLSI
values, for the detection of ESBL.
Overall, this study shows that EUCAST non-susceptible break-
points for cefotaxime and ceftazidime with corresponding
EUCAST disc contents may be used without loss of performance
compared with CLSI ESBL screening breakpoints. Using the
EUCAST non-susceptible breakpoints for ceftriaxone will slightly
decrease sensitivity compared with the CLSI ESBL screening
breakpoint. However, using the EUCAST non-susceptible break-
point for cefpodoxime will result in a sensitivity of 100% with
specificity marginally decreased compared with the CLSI ESBL
screening breakpoint.
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Furthermore, EUCAST recommends lower antibiotic disc con-
tents for ceftazidime and cefotaxime compared with CLSI. Evalu-
ation of the influence of the new disc contents on the
performance of the commonly applied DAM for ESBL detection
and confirmation was another aim of this study. The sensitivities
of DAM with ceftazidime and cefotaxime were found to be inde-
pendent of disc contents of CLSI and EUCAST, respectively;
however, these are dispensable for routine use, since other
markers showed a higher sensitivity. Cefepime DAM and the
EUCAST resistant breakpoint for cefpodoxime proved to be the
most sensitive markers for screening of potential ESBL producers.
Notably, cefepime synergy showed a sensitivity of 100% in iso-
lates producing chromosomally encoded or plasmid-encoded
AmpC b-lactamases. Our results are in agreement with other
studies that found cefepime to be the most suitable substance
for screening and confirmation of ESBL-producing isolates that
also produce AmpC.30,31 Thus, for AmpC-positive isolates such
as Enterobacter spp., but also for isolates with plasmid-encoded
AmpC, cefepime DAM may be used as a sole screening marker
for ESBL. Taking into account the high specificity (97.9%) of the
cefepime DAM, positive isolates may even be reported as ESBL-
positive without further confirmation.
In conclusion, changing from CLSI to EUCAST breakpoints for
ESBL detection will retain or even enhance sensitivity for ESBL
detection. The fear that large proportions of ESBL-producing
organisms will be reported susceptible to third- and fourth-
generation cephalosporins could not be substantiated.
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